FreeGulliver LLC’s Starling Oncology Institute, Inc. Common Stock STLN Stock Holding History

FreeGulliver LLC’s Portfolio STLN Stock Details STLN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	–	Sell	-355,672	Closed	-$1.27M	–	133
2025 Q4	$1.27M	Buy	355,672 +145,672	+69%	+$540K	0.47%	30
2025 Q3	$733K	Sell	210,000 -133,800	-39%	-$458K	0.33%	42
2025 Q2	$705K	Sell	343,800 -200,561	-37%	-$501K	0.32%	39
2025 Q1	$621K	Sell	544,361 -56,386	-9%	-$43.7K	0.31%	40
2024 Q4	$186K	Buy	600,747 +412,578	+219%	+$107K	0.09%	88
2024 Q3	$61.5K	Hold	188,169	–	–	0.04%	81
2024 Q2	$86.6K	Hold	188,169	–	–	0.06%	80
2024 Q1	$297K	Buy	188,169 +123,169	+189%	+$234K	0.26%	41
2023 Q4	$133K	Buy	+65,000	New	+$113K	0.18%	42

Other funds holding STLN

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return

KWM

Kanen Wealth Management Coconut Creek, Florida $278M AUM 38.85% 1-Year Est. Return

JAIC

Josh Arnold Investment Consultant Edina, Minnesota $117M AUM 26.5% 1-Year Est. Return

Balyasny Asset Management Chicago, Illinois $77.1B AUM 42.89% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Wexford Capital West Palm Beach, Florida $690M AUM 57.88% 1-Year Est. Return

CenterBook Partners Greenwich, Connecticut $1.86B AUM 24.52% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

FreeGulliver LLC's STLN Position: Q1 2026 in Review

FreeGulliver LLC sold out of Starling Oncology Institute, Inc. Common Stock (STLN) in Q1 2026, closing a stake of 355,672 shares — an estimated $1.27M sold.

FreeGulliver LLC first reported a position in STLN in Q4 2023 and held it in 9 quarters. The position peaked at $1.27M in Q4 2025. 115 funds tracked by Wall St. Rank hold STLN as of Q1 2026.

FreeGulliver LLC reported no remaining Starling Oncology Institute, Inc. Common Stock position as of Q1 2026 after selling out during the quarter.
FreeGulliver LLC sold 355,672 Starling Oncology Institute, Inc. Common Stock shares in Q1 2026, an estimated $1.27M.
FreeGulliver LLC first reported a position in Starling Oncology Institute, Inc. Common Stock in Q4 2023 and held it in 9 quarters.
FreeGulliver LLC's Starling Oncology Institute, Inc. Common Stock position peaked at $1.27M in Q4 2025.
115 funds tracked by Wall St. Rank held Starling Oncology Institute, Inc. Common Stock as of Q1 2026.

Based on FreeGulliver LLC's 13F filing for Q1 2026, filed 15 May 2026.